New Findings on Immunodeficiency Disease from Baxalta Innovations GmbH Summarized (Long-term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment In Us Clinical Practice In Patients With Primary Immunodeficiency Diseases: Results...).

Details

Language :

English

ISSN :

15316440

Database :

Complementary Index

Journal :

Drug Week

Publication Type :

Periodical

Accession number :

181136964